Automation in clinical LC-MS/MS
LC-MS-based testing offers accuracy, specificity, and a high speed of analysis, which is why it is being adopted across many clinical laboratories.
Milestone reached for IVDR
As an important milestone, Chromsystems has received its IVDR certification from its notified body, which already covers the IVDR conformity for the first products.
Robotic Solution for Clinical LC-MS/MS
MassSTAR is a CE-validated full walkaway solution specifically designed for automating clinical LC-MS/MS sample preparation with Chromsystems assays.
Amino Acid Analysis (AAA) in Urine with LC-MS/MS
A new Chromsystems assay enables the quantitative determination of 52 amino acids by LC-MS/MS in urine. Creatinine is also measured within the same run. The assay can be easily combined with the plasma kit.
CSQUANT® Simplifies LC-MS/MS Data Analysis
Clinical laboratories performing routine LC-MS/MS are required to evaluate large amounts of data. The new Data Mining Software CSQUANT® helps to simplify and accelerate the evaluation of the data.
Product Information Leaflets in Excel Format
Every package of calibrators and controls contains a product insert with necessary target values and calibrator concentrations. To make the data transfer more efficient, we are now providing Excel files of the inserts.
Article: TDM in ECMO Patients
During extracorporeal membrane oxygenation intensive care patients receive various antibiotics. If these drugs are not measured regularly, then patients are at risk of being underdosed and are unlikely to meet the MIC.
Study: Time to Rethink Amino Acid Analysis (AAA)
Quantitative AAA requires high sensitivity and specificity. Over the years, the gold standard technique has been Ion Exchange Chromatography (IEC). As with most techniques, IEC does have some drawbacks. A recent study by Carling et al suggests that it might be time to rethink quantitative amino acid analyses and compared IEC with LC-MS/MS as an alternative method.
App Note: Therapeutic Drug Monitoring of Immunosuppressants with MassTox® Series A
Customers can use this protocol on a research-use basis, which demonstrates the analysis of more than 200 drugs plus immunosuppressants in the laboratory while also eliminating the need for changes to the chromatographic setup.
Article: New EU Regulation for In-Vitro Diagnostics (IVDR)
What benefits does IVDR bring to manufacturers and laboratories?
Challenges and opportunities of the new diagnostics regulation.
Educational Webinar: Challenging the Status Quo of Amino Acid Analysis in Plasma
Dr. Rachel Carling, Scientific Director for Viapath, reports in this recorded webinar on a study that compares the current gold standard in quantitative amino acid analysis (AAA) - ion exchange chromatography (IEC) - with LC-MS/MS.
Scientific Paper: Vitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2
A new study investigated the potential relationship between vitamin D blood concentrations and SARS-CoV-2 infections. Is the risk of an infection and the disease severity influenced by the vitamin D status? The scientists used the MassChrom® Vitamin D assay on a MassSTAR automation system.
List: Metabolism Disorders in Amino Acid Profile
This table features exemplary amino acid metabolism disorders and associated changes in the amino acid profile that are covered by the MassChrom Amino Acid Analysis (AAA) assay.
UDI Labelling of Our Products
We are currently integrating the new UDI code on our labels as part of the Unique Device Identification (UDI) System. UDIs are required only in the United States so far, but will become mandatory in Europe when the new IVDR comes into effect.
Article: Traceability in Clinical Diagnostics
The ultimate aim of traceability is to ensure that analytical results used for patient care are accurate as well as comparable over time and location. What we do to achieve that? Learn more in this article.
Article: Therapeutic Drug Monitoring in Intensive Care
This article discusses the importance of appropriate drug concentrations in antibiotic therapies to and help prevent over- and underdosing. This approach also reduces the risk of new multidrug resistant strains emerging and helps to provide the most effective drug dose to the patient.